- Home
- GH vs TREX Comparison
GH vs TREX Comparison
Compare GH & TREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- TREX
- Stock Information
- Founded
- GH 2011
- TREX 1996
- Country
- GH United States
- TREX United States
- Employees
- GH N/A
- TREX N/A
- Industry
- GH Medical Specialities
- TREX
- Sector
- GH Health Care
- TREX
- Exchange
- GH Nasdaq
- TREX Nasdaq
- Market Cap
- GH 6.1B
- TREX N/A
- IPO Year
- GH 2018
- TREX 1999
- Fundamental
- Price
- GH $40.64
- TREX $54.00
- Analyst Decision
- GH Strong Buy
- TREX Buy
- Analyst Count
- GH 20
- TREX 16
- Target Price
- GH $48.40
- TREX $78.63
- AVG Volume (30 Days)
- GH 2.6M
- TREX 2.1M
- Earning Date
- GH 05-08-2025
- TREX 05-08-2025
- Dividend Yield
- GH N/A
- TREX N/A
- EPS Growth
- GH N/A
- TREX 10.59
- EPS
- GH N/A
- TREX 2.09
- Revenue
- GH $739,016,000.00
- TREX $1,151,449,000.00
- Revenue This Year
- GH $19.11
- TREX $8.39
- Revenue Next Year
- GH $21.44
- TREX $8.57
- P/E Ratio
- GH N/A
- TREX $26.33
- Revenue Growth
- GH 31.04
- TREX 5.17
- 52 Week Low
- GH $15.81
- TREX $52.75
- 52 Week High
- GH $50.89
- TREX $100.77
- Technical
- Relative Strength Index (RSI)
- GH 46.62
- TREX 25.38
- Support Level
- GH $34.88
- TREX $52.75
- Resistance Level
- GH $45.00
- TREX $55.73
- Average True Range (ATR)
- GH 3.11
- TREX 2.37
- MACD
- GH -0.28
- TREX -0.46
- Stochastic Oscillator
- GH 51.89
- TREX 11.30
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.